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20-OMe-phosphorodithioate-modiﬁed siRNAs
show increased loading into the RISC complex
and enhanced anti-tumour activity
Sherry Y. Wu1,*, Xianbin Yang2,*, Kshipra M. Gharpure1, Hiroto Hatakeyama1, Martin Egli3, Michael H. McGuire1,
Archana S. Nagaraja1, Takahito M. Miyake1, Rajesha Rupaimoole1, Chad V. Pecot4, Morgan Taylor1,
Sunila Pradeep1, Malgorzata Sierant5, Cristian Rodriguez-Aguayo6,7, Hyun J. Choi1, Rebecca A. Previs1,
Guillermo N. Armaiz-Pena1, Li Huang8, Carlos Martinez9, Tom Hassell9, Cristina Ivan1,7, Vasudha Sehgal10,
Richa Singhania11,12, Hee-Dong Han1,7,13, Chang Su1, Ji Hoon Kim10,14, Heather J. Dalton1, Chandra Kovvali1,
Khandan Keyomarsi15, Nigel A.J. McMillan11,16, Willem W. Overwijk17, Jinsong Liu18, Ju-Seog Lee10,
Keith A. Baggerly19, Gabriel Lopez-Berestein6,7, Prahlad T. Ram10, Barbara Nawrot5 & Anil K. Sood1,7,8
Improving small interfering RNA (siRNA) efﬁcacy in target cell populations remains a
challenge to its clinical implementation. Here, we report a chemical modiﬁcation, consisting of
phosphorodithioate (PS2) and 20-O-Methyl (20-OMe) MePS2 on one nucleotide that
signiﬁcantly enhances potency and resistance to degradation for various siRNAs. We ﬁnd
enhanced potency stems from an unforeseen increase in siRNA loading to the RNA-induced
silencing complex, likely due to the unique interaction mediated by 20-OMe and PS2. We
demonstrate the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer
mouse models via targeting GRAM domain containing 1B (GRAMD1B), a protein involved in
chemoresistance. GRAMD1B silencing is achieved in tumours following MePS2-modiﬁed
siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel.
Given the previously limited success in enhancing siRNA potency with chemically modiﬁed
siRNAs, our ﬁndings represent an important advance in siRNA design with the potential for
application in numerous cancer types.
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S
mall interfering RNA (SiRNA)-based therapies have shown
promise in recent clinical trials as anti-cancer agents1,2.
This technology offers tremendous potential in silencing
‘non-druggable’ targets that are not amenable to conventional
therapeutics such as small molecules or monoclonal antibodies3,4.
However, the lack of stability and low potency at target sites
following systemic administration remain the major obstacles to
clinical translation of this therapy5,6.
To overcome these problems, efforts have been made to
chemically modify the 20-position of the ribose moiety (for
example, 20-OMe or 20-F) or phosphate backbone of the siRNA
molecule (for example, phosphoromonothioate (PS) modiﬁca-
tion) such that enhanced serum stability7, bioavailability8 and
prolonged duration of action9 could be achieved (Reviewed in
ref. 10). Importantly, combining PS and 20-modiﬁcation impart
superior stability over single modiﬁcations11,12, leading to the
approval of Kynamro, an antisense therapeutic, by the Food and
Drug Administration13.
Despite the advance, combination of PS and 20-modiﬁcation
shows limited enhancement of siRNA potency14. Moreover,
synthesis of PS or MePS by standard phosphoramidite methodo-
logy also generates a mixture of unresolvable diastereomeric
oligomers, which could potentially result in variable biochemical,
biophysical and biological properties. We have recently reported
that PS2 modiﬁcation, which substitutes sulphur atoms for both
of the non-bridging phosphate and oxygen atoms, signiﬁcantly
improves serum stability and gene silencing over PS-modiﬁed
siRNAs15. Its achiral nature at the phosphorous centre eliminates
the generation of isomeric by-products, thereby permitting
batch–to-batch quality control16,17, a feature that cannot be
achieved with the MePS platform. As such, PS2-modiﬁed siRNA
is a prime candidate for introducing critical new features to
further improve siRNA efﬁcacy both in vitro and in vivo.
We hypothesized that the incorporation of two most widely
used sugar modiﬁcations, 20-OMe or 20-F, into a PS2-modiﬁed
construct could lead to further enhancement of the PS2 siRNA
stability and increase their clinical potential. In this study, we
show that the novel MePS2 design signiﬁcantly enhances serum
stability and silencing activity of siRNAs. This enhanced potency
stems from an unforeseen increase in the loading of siRNAs to
the RNA-induced silencing complex (RISC). We further
demonstrate the therapeutic utility of MePS2-modiﬁed siRNAs
by targeting GRAM domain containing 1B (GRAMD1B), a novel
gene identiﬁed through a whole-genome, taxane sensitivity
screen. Given that limited success has been achieved thus far
towards broadly enhancing siRNA potency with chemically
modiﬁed siRNAs18–20, MePS2 modiﬁcation represents a major
new direction for enhancing the clinical application of existing
RNA interference (RNAi)-based therapies.
Results
Synthesis and activity of chemically modiﬁed siRNAs. To
investigate the gene-silencing activity of MePS2– or FPS2–
siRNAs and to gain insight into their regulation of the RNAi
pathway, we ﬁrst synthesized these novel siRNAs via the solid-
phase synthesis technique. Given our extensive experience in
using unmodiﬁed (UM) siRNAs to target EPH receptor A2
(EphA2), a tyrosine kinase receptor that promotes tumour pro-
gression in cancer21, we chose to initially evaluate our novel
siRNAs using EphA2 as a model system. We have previously
identiﬁed favourable positions of PS2 modiﬁcation using a siRNA
that targets green ﬂuorescence protein (Supplementary Fig. 1;
Supplementary Table 1). The silencing efﬁcacy of selected
PS2-modiﬁed sequences was further validated using another
siRNA sequence15. Informed by these prior observations, we
designed MePS2/FPS2-1 through -3 constructs for siEphA2
(Fig. 1, Table 1). We also created MePS2/FPS2-4 sequences,
where there are two MePS2/FPS2 groups present at the seed
region of the antisense strand. Finally, counterpart sequences
were synthesized with either 20-OMe/20-F alone, PS2 alone or
MePS/FPS placed at the same locations.
SKOV3ip1 and HeyA8, both epithelial ovarian cancer (OvCa)
cell lines that highly express EphA2, were transfected with
synthesized siRNAs in serum-free conditions to test silencing
efﬁcacy. Two independent experiments were performed and
EphA2 protein quantiﬁcation was done at 48 h post transfection.
MePS2-1, MePS2-2, Me-4, FPS-1, FPS-4 and F-1 signiﬁcantly
decreased EphA2 levels in SKOV3ip1 compared with UM siRNA
and outperformed their counterparts (Fig. 2a). In particular, we
found that the MePS2-1 modiﬁcation silenced EphA2 to a much
greater degree compared with UM (sixfold enhancement). It also
showed 4, 7.5 and 7-fold enhancement in EphA2 silencing
compared with PS2-1-, MePS-1- and Me-1-modiﬁed sequences,
respectively. In contrast to MePS2-1 and MePS2-2, FPS2-1 and
FPS2-2 modiﬁcations did not increase silencing efﬁciency of the
siRNA. Given the signiﬁcant improvement in gene silencing
observed with MePS2-1, we focused our subsequent effort on
Me-modiﬁed constructs. In HeyA8 cells, MePS2-1-modiﬁed
siEphA2 also showed superior silencing activity compared with
the UM sequence (80% versus 50% knockdown, respectively,
Fig. 2b). Interestingly, both PS2-1- and PS2-2-modiﬁed sequences
resulted in signiﬁcant silencing of EphA2 in this cell line.
Given the promise of the MePS2-1 modiﬁcation in both
of the cell lines examined, we next investigated the impact of
different modiﬁcations at the same position on gene silencing and
serum stability (Supplementary Fig. 2; Fig. 2c,d). To mimic the
condition in the preclinical or clinical setting, sequences
were introduced into SKOV3ip1 cells in media containing 10%
fetal bovine serum (FBS). EphA2 protein levels were examined
48 h post transfection. MePS2-1 displayed a signiﬁcant
improvement over all other sequences tested, including PS2-1
(Fig. 2c; Supplementary Fig. 3). Of note, further modiﬁcations at
different positions of the MePS2-1 siEphA2 sequence resulted in
reduced silencing efﬁciency (Supplementary Fig. 4). The
improved gene silencing as the result of MePS2-1 modiﬁcation
was also observed when another siRNA sequence was used
(parathymosin-targeted siRNA, Supplementary Fig. 5a). SiRNA
stability assays show that the majority of UM siRNA was broken
down within 20min, with near-complete degradation at 3 h
(Fig. 2d). Overall improvements in serum stability were seen for
all modiﬁed sequences in comparison to UM, but MePS2-1
displayed the highest sequence stability, with a large portion of
the input molecules remaining intact at 3 h. An even greater
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Figure 1 | Chemical structures of modiﬁed siRNAs. Chemical structures of
modiﬁed siRNAs used for the initial screen.
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enhancement in stability was observed with parathymosin-
targeted siRNA (Supplementary Fig. 5b).
We next wondered if the enhanced stability after modiﬁcation
accounted for these constructs’ increased silencing efﬁcacy. To
test this, we employed stemloop polymerase chain reaction (PCR)
technique to quantify intact siRNA within the cell following
transfection (Fig. 2e; Supplementary Fig. 5c). Increased intracel-
lular siRNA stability via MePS2 modiﬁcation was conﬁrmed, but
not to a degree that would explain its dramatic increase in siRNA
potency. Our conclusion was that MePS2-1 showed increased
potency independent of improvements in stability. This was
consistent with the ﬁnding that the duration of silencing was not
signiﬁcantly prolonged for MePS2-1 sequence compared with the
UM counterpart (Fig. 2f).
Biophysical properties of MePS2-1 siRNA. We examined the
mechanism by which MePS2-1 sequence enhances the gene-
silencing effect. First, we examined thermodynamic stability
(measured by RNA duplex melting temperature (Tm)) since the
destabilization of the 50-end of duplex by introducing modiﬁed
units into 30-end of the sense strand is crucial in creating
favourable thermodynamic asymmetry for siRNA activity15,22,23.
Measuring the Tm of MePS2-1 and its counterpart sequences
showed MePS2-1 to have the largest decrease in Tm (1.24 C,
DTm, Po0.05) when compared with UM siRNA, suggesting
duplex unwinding may have a role in its enhanced RNAi activity
(Table 2). Importantly, in contrast to 20-OMe modiﬁcation alone
which increased Tm, its addition at the site of PS2 modiﬁcation
did not elevate Tm.
We also hypothesized that the MePS2 modiﬁcation may
potentially alter helix conformation between the target and guide
strand by changing local structure, which can affect silencing
activity24,25. However, circular dichroism (CD) spectra of all the
modiﬁed sequences tested were similar to the spectrum of UM
duplexes and are consistent with the typical A-type structure
(a maximum of the positive Cotton effect at 268 nm and a
crossover point at 240 nm) (Fig. 3a).
Our next hypothesis was that the thiol groups on MePS2-1’s
phosphate backbone may interact with metal ions or amino-acid
residues in RISC to increase the sequence’s afﬁnity for
the complex26,27. We tested this hypothesis by transfecting
UM, PS2-1 and MePS2-1 into SKOV3ip1 cells, then
immunoprecipitating argonaute-2 (Ago2). SiEphA2 with two
20-OMe residues at the 50-end of the sense strand
(Me2-siEphA2)28 was used as a positive control. From a panel
of 10 different microRNAs (miRNA) tested, hsa-miR-484 was
found to be both unaffected by siEphA2 and present at a
high level in SKOV3ip1 cells, thus we chose it as our
normalizing control (Supplementary Fig. 6). We found that
Ago2-associated MePS2-1 and PS2-1 sequences were enriched
sevenfold and threefold compared with UM siRNA, respectively
(Fig. 3b). In contrast to UM siRNA where the level of associated
Ago2 protein was below the limit of detection via western
blotting, a high level of siRNA-associated Ago2 was detected for
both PS2-1 and MePS2-1 siRNAs in the biotin-siRNA pull-
down study (Fig. 3c). In both of these experiments, there was a
signiﬁcant increase in Ago2 binding for MePS2-1 compared
with PS2-1 sequence (greater than twofold). The ability of
MePS2-1 modiﬁcation to enhance loading of siRNAs into RISC
was also demonstrated using another siRNA sequence
(Supplementary Fig. 5d). Of note, the enhanced binding of
MePS2-1 siRNAs to RISC had minimal effect on miR biogenesis
(Supplementary Fig. 7).
Table 1 | Chemical structures of modiﬁed siRNAs.
Sense (50–30) Antisense (30–50)
UM UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUAGAUGUAC
PS2-1 UGACAUGCCGAUCUACAUS2GS2TT TTACUGUACGGCUAGAUGUAC
PS2-2 UGAS2CAUGCCGAUS2CUACAUGTT TTACUGUACGGCUAGAUGUAC
PS2-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGS2GS2CUAGAUGUAC
PS2-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUS2AGAUS2GUAC
MePS2-1 UGACAUGCCGAUCUACAUMeS2GMeS2TT TTACUGUACGGCUAGAUGUAC
MePS2-2 UGAMeS2CAUGCCGAUMeS2CUACAUGTT TTACUGUACGGCUAGAUGUAC
MePS2-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGMeS2GMeS2CUAGAUGUAC
MePS2-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUMeS2AGAUMeS2GUAC
MePS-1 UGACAUGCCGAUCUACAUMeSGMeSTT TTACUGUACGGCUAGAUGUAC
MePS2 UGAMeSCAUGCCGAUMeSCUACAUGTT TTACUGUACGGCUAGAUGUAC
MePS-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGMeSGMeSCUAGAUGUAC
MePS-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUMeSAGAUMeSGUAC
Me-1 UGACAUGCCGAUCUACAUMe GMeTT TTACUGUACGGCUAGAUGUAC
Me2 UGAMeCAUGCCGAUMeCUACAUGTT TTACUGUACGGCUAGAUGUAC
Me-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGMeGMeCUAGAUGUAC
Me-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUMeAGAUMeGUAC
FPS2-1 UGACAUGCCGAUCUACAUFS2GFS2TT TTACUGUACGGCUAGAUGUAC
FPS2-2 UGAFS2CAUGCCGAUFS2CUACAUGTT TTACUGUACGGCUAGAUGUAC
FPS2-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGFS2GFS2CUAGAUGUAC
FPS2-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUFS2AGAUFS2GUAC
FPS-1 UGACAUGCCGAUCUACAUFSGFSTT TTACUGUACGGCUAGAUGUAC
FPS2 UGAFSCAUGCCGAUFSCUACAUGTT TTACUGUACGGCUAGAUGUAC
FPS-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGFSGFSCUAGAUGUAC
FPS-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUFSAGAUFSGUAC
F-1 UGACAUGCCGAUCUACAUFGFTT TTACUGUACGGCUAGAUGUAC
F-2 UGAFCAUGCCGAUFCUACAUGTT TTACUGUACGGCUAGAUGUAC
F-3 UGACAUGCCGAUCUACAUGTT TTACUGUACGFGFCUAGAUGUAC
F-4 UGACAUGCCGAUCUACAUGTT TTACUGUACGGCUFAGAUFGUAC
Chemical structures of modiﬁed siRNAs used for the initial screen. Locations of modiﬁcation are indicated for each sequence.
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We further investigated the impact of MePS2-1 modiﬁcation
on strand loading. SKOV3ip1 cells were transfected with siEphA2
sense (S) and antisense (AS) strand-speciﬁc luciferase reporters.
MePS2-1(S) decreased the luciferase signal to a much greater
degree (2.2-fold enhancement) compared with UM siRNA in cells
transfected with the AS reporter construct (Supplementary
Fig. 8a). As expected, MePS2-1(AS) did not reduce the luciferase
signal signiﬁcantly when compared with control siRNA (siCon)
treatment. Conversely, in cells transfected with the S reporter
construct, MePS2-1(AS) further improved the silencing ability of
the siRNAs when compared with the UM sequence, while no
silencing was observed with MePS2-1(S) (Supplementary Fig. 8b).
We further compared the silencing efﬁcacy of MePS2-1(S) with
Me2(S)-siRNA. In cells transfected with the AS reporter
construct, Me2(S) siRNAs decreased the luciferase signal to a
greater extent compared with UM, as expected (Supplementary
Fig. 8a). This extent of silencing was comparable with that
achieved by MePS2-1(S). The addition of MePS2-1(S)
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Figure 2 | Stability and gene-silencing activity of chemically modiﬁed siRNA. (a) Knockdown of EphA2 in SKOV3ip1 cells using chemically modiﬁed
siRNAs (100nM, serum-free condition). (b) Knockdown of EphA2 using selected siRNA sequences in HeyA8 cells (100 nM, serum-free condition).
(c) Knockdown of EphA2 using chemically modiﬁed siRNAs in SKOV3ip1 cells (10, 20 and 50 nM, 10% FBS-containing media). (a–c) Cells were treated
with siRNAs for 4 h and EphA2 protein levels were examined 48 h post transfection. (d) Stability of chemically modiﬁed siRNAs in 10% FBS at 37 C.
(e) Intracellular stability of UM and MePS2-1-modiﬁed siEphA2 in SKOV3ip1 cells (50 nM, serum-free condition). (f) Duration of EphA2 knockdown
following UM and MePS2-1-modiﬁed siEphA2 treatment in SKOV3ip1 cells (50 nM, 10% FBS-containing media). (P-values obtained with Student’s t-test;
*Po0.05; **Po0.01; ***Po0.001; or ****Po0.0001; compared with UM siEphA2 sequence; bars and error bars represent mean values and the
corresponding s.e.m.s (n¼ 3).)
Table 2 | Thermostability of chemically modiﬁed siRNAs.
siRNA sequence Average Tm (C) s.d. (C) DTm (C)
UM 76.51 0.64 N/A
Me-1 76.68 0.50 0.17
PS-1 75.91 0.65 0.60
MePS-1 76.37 0.08 0.14
PS2-1 75.82 0.50 0.69
MePS2-1 75.27 0.07  1.24
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modiﬁcation to Me2(S)-siRNA (Me2MePS2-1) did not signiﬁ-
cantly alter its silencing efﬁciency. These results are consistent
with the level of EphA2 mRNA knockdown observed with these
siRNAs (Supplementary Fig. 8c).
We used computational modelling to examine the potential
effects of the MePS2 modiﬁcation on the interaction of siRNAs
with RIC, focusing on the PAZ domain that recognizes
30-overhanging nucleotides of siRNA duplexes29. In the crystal
structure, the siRNA 50-(CGUGACU)-d(CU)-30 forms a duplex
with one G-G and two U-C mismatch pairs and 30-terminal
d(CU) overhangs. Modelling entailed changing the penultimate
30-dC to T, converting the terminal RNA U-C pair in the native
duplex to G:C, and changing the adjacent G:C pair to A:U.
Methyl groups were also added to the sugar 20-oxygen atoms
of U and G in the antiperiplanar orientation (torsion angle
C30-C20-O20-Cmethyl (ref. 30)). Inspection of the model of MePS2-1
bound to PAZ indicates that the combination of the 20-OMe and
PS2 modiﬁcations will likely beneﬁt the interaction between siRNA
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binding of UM, PS2-1, MePS2-1 and Me2 modiﬁed siEphA2 to Ago2 protein in SKOV3ip1 cells (50 nM, serum-free condition). (c) Ago2 association
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(c) ****Po0.0001; compared with respective controls; (e) **Po0.01; ***Po0.001; compared with UM siCon; (f,g) *Po0.05 or **Po0.01; compared
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and PAZ (Fig. 3d). Thus, the proximities of the 20-OMe moiety of
G and CE of M273 as well as the PS2 moiety of T and both CE
of Met273 and the sulfhydryl group of C270 are consistent
with favourable hydrophobic interactions that are absent in the
complex with the UM siRNA and are superior to those for the
Me-1 and PS2-1 siRNAs. Taken together, the combination of PS2
and 20-OMe modiﬁcation triggers an unusual stereoelectronic
effect in the backbone of the siRNA, which leads to increased
RISC loading. This, along with an increase in resistance to
nuclease degradation as well as a decrease in Tm, provides a
likely explanation for enhanced RNAi activity by MePS2-1
modiﬁcation.
In vivo application of MePS2-1 siRNA. Having identiﬁed a
promising chemical modiﬁcation that could signiﬁcantly enhance
the stability and silencing activity of siRNAs, we next character-
ized its potential off-target immunotoxicity. C57BL/6-derived
dendritic cells were treated with UM siCon, UM siEphA2,
MePS2-1 siCon and MePS2-1 siEphA2. Interferon alpha (IFN-a)
levels, a surrogate marker for non-speciﬁc induction of innate
immunity, were similar for all four sequences examined (Fig. 3e).
No difference in Toll-like receptor 7 (TLR7)-induced IFN-a or
tumour necrosis factor alpha (TNF-a) levels was observed
between UM siEphA2 and MePS2-1 siEphA2 at all time
points examined (Supplementary Fig. 9). Of note, serum
IFN-a and TNF-a levels were both undetectable at 2, 6 and
24 h following intraperitoneal (i.p.) administration of 1,2-dio-
leoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes-
delivered UM-siEphA2 (UM-siEphA2-DOPC) or MePS2-1
siEphA2 (MePS2-1-siEphA2-DOPC) in mice.
The efﬁcacy of the MePS2-1 siRNA in vivo was next assessed
using an orthotopic mouse model of OvCa (SKOV3ip1). The
effect of EphA2 knockdown in tumours was ﬁrst examined
following a single injection. While some degree of knockdown
was achieved with MePS2-1-siEphA2-DOPC at the dose of
1.25 mg, (Fig. 3f), 42.5 mg per dose was determined to be
necessary to achieve consistent and signiﬁcant gene silencing in
tumours. At the dose of 2.5 mg, measurement of EphA2 by
western blot of tumour lysate revealed superior gene-silencing
effect of MePS2-1-siEphA2-DOPC compared with UM-siEphA2-
DOPC (80% versus 30% reduction, respectively). We next treated
mice with 2.5 mg of UM-siCon-DOPC, UM-siEphA2-DOPC,
MePS2-1-siCon-DOPC and MePS2-1-siEphA2-DOPC twice
weekly (n¼ 10). After 4 weeks of therapy, the animals were
killed and necropsies were performed. UM-siEphA2-DOPC
reduced the tumour burden compared with UM-siCon-DOPC
group (50% reduction); however, the difference is not statistically
signiﬁcant. In contrast, MePS2-1-siEphA2-DOPC exhibited
signiﬁcant reduction in tumour weight (Fig. 3g, 70% reduction)
compared with the MePS2-1-siCon-DOPC treatment group. No
group showed decreased body weight, one major indicator of
toxicity (Fig. 3h). Overall, these results demonstrate superior
gene-silencing and therapeutic effects with MePS2-1-siEphA2-
DOPC compared with UM-siEphA2-DOPC.
We next evaluated the pharmacokinetic proﬁle and
biodistribution pattern of MePS2-1-siEphA2-DOPC following a
single i.p. injection in tumour-bearing mice. The level of siRNAs
accumulated in tumours was found to be signiﬁcantly higher
than that observed in other major organs, including the lung,
heart, liver, spleen, kidneys and brain (Fig. 3i). The localization of
DOPC nanoliposomes to tumours was further conﬁrmed using
Cy5.5-labelled siRNAs (Supplementary Fig. 10). This ability of
DOPC nanoliposomes to preferentially deliver siRNAs to
tumours while avoiding signiﬁcant uptake in other organs is
similar to that observed with several other systems, including
pRNA nanoparticles31. The pharmacokinetic analysis of MePS2-
1-siEphA2-DOPC showed an area under the curve (AUC)0-72
of 477 pg h 1ml 1, clearance of 5.23 l h 1, and volume of
distribution of 26.3 l. Distribution half-life of MePS2-1-siEphA2-
DOPC was 3.7min and the elimination half-life was 9.3 h.
Targeting GRAMD1B for OvCa treatment. Having demon-
strated that MePS2-1 siRNA has superior gene-silencing activity
compared with its UM counterpart for an established target, we
next assessed its silencing, and in turn, therapeutic capability for
an OvCa target gene. Since acquired chemoresistance is a major
contributor to patient mortality from OvCa, we sought to identify
targets having substantial roles in this process. SiRNAs against
approximately 22,000 individual genes were evaluated for their
lethality and ability to induce taxane sensitivity in taxane-resis-
tant epithelial OvCa cells (SKOV3-TR) (Supplementary Data 1).
High correlation between cell viability score was observed
across triplicate plates (median coefﬁcient of variation¼ 8.6%),
indicating high data precision in the screen.
A total of 178 genes were identiﬁed to have reduced cell
viability upon siRNA treatment and showed further cell death
when combined with paclitaxel (Supplementary Data 2).
Importantly, the dose of paclitaxel used in the screen was IC30
of that achieved in parental taxane-sensitive SKOV3ip1 cells to
permit identiﬁcation of genes that, when silenced, can dramati-
cally sensitize cells to taxane treatment. Out of 178 hits, eight
genes were identiﬁed to be up-regulated in OvCa epithelial cells
compared to normal ovarian surface epithelial cells32 (Fig. 4a).
Within this group, we focused on three genes associated with the
highest lethality upon knockdown when combined with
paclitaxel: GRAMD1B, RBBP6 and SLC23A1. We found that
taxane-resistant OvCa cell lines (HeyA8-MDR, SKOV3-TR)
showed elevated levels of GRAMD1B mRNA and protein
relative to their sensitive counterparts (HeyA8, SKOV3ip1)
(Fig. 4b,c). The expression of GRAMD1B remained unchanged
for platinum resistant A2780-CP20 cells when compared with the
parental line (A2780), indicating the lack of involvement of this
gene in platinum resistance. GRAMD1B was also conﬁrmed to be
highly elevated in HeyA8 and SKOV3ip1 compared with the non-
transformed HIO-180 ovarian epithelial cells. RBBP6 and
SLC23A1 mRNA expression levels, although elevated in some
OvCa lines, were not found to be increased in resistant cell lines
examined (Fig. 4b).
We next examined the effect of silencing GRAMD1B in the
taxane-resistant cell line with the highest target expression,
HeyA8-MDR (Supplementary Data 3, Supplementary Fig. 11, and
Fig. 4d,e). GRAMD1B silencing via introducing siGRAMD1B
into cells using Lipofectamine 2000 exhibited both lethality as
monotherapy (40% decrease in cell viability and 3-fold increase in
apoptosis, Fig. 4d,e) and also taxane sensitization at 10 nM
paclitaxel (475% versus o5% cell death, siGRAMD1B plus
paclitaxel versus siCon plus paclitaxel) (Fig. 4f). Treatment with
docetaxel produced a similar pattern. Signiﬁcant taxane sensitiza-
tion was also observed when another GRAMD1B-targeting
siRNA was transfected into cells using another transfecting
reagent, Lipofectamine RNAiMax (Supplementary Fig. 12). These
results indicate the potential of GRAMD1B silencing in over-
coming taxane resistance in OvCa.
Given the preclinical efﬁcacy after targeting GRAMD1B, we
subsequently assessed the impact of tumoral GRAMD1B expres-
sion on patient survival. Immunohistochemical GRAMD1B
expression was analysed against the clinical characteristics of a
cohort of 156 women with mostly advanced epithelial OvCa
(Supplementary Table 2). High tumoral GRAMD1B expression
was signiﬁcantly associated with several indicators of aggressive
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disease, including suboptimal cytoreductive surgery (50% versus
33%, P¼ 0.04, w2 test), progressive or recurrent disease (92.6%
versus 74.5%, P¼ 0.004, w2 test), lower median progression-free
survival (0.9 versus 1.72 years, P¼ 0.001, log-rank test) and lower
overall survival (OS, 3.59 versus 6.14 years, P¼ 0.01, log-rank
test, Fig. 4g). GRAMD1B expression remained an independent
predictor of survival following multivariate analysis accounting
for age, stage, grade, extent of cytoreduction and GRAMD1B
expression (P¼ 0.02, Cox proportional-hazards model). We
further investigated the relationship between tumoral GRAMD1B
expression and chemotherapy response in a subset of OvCa
patients (n¼ 32) who had suboptimal tumour debulking at the
time of surgery (that is, 41 cm residual disease). Cancer antigen
125 (CA125) was used as a measure of drug response33. Patients
who had CA125 level normalized to 35 at the end of six cycles of
chemotherapy were considered responsive to treatments. It was
found that 89% of patients with high tumoral GRAMD1B protein
expression levels responded poorly to chemotherapy (that is,
CA125435 at the end of six cycles of chemotherapy). In contrast,
patients whose tumour had low GRAMD1B expression
responded signiﬁcantly better to chemotherapy (Po0.001,
w2 test), with 91.3% of patients having normalized CA125 at
the end of the therapy. Median progression-free survival was 0.61
and 2.07 years for patients with high versus low tumoral
GRAMD1B expression, respectively (Supplementary Fig. 13).
Therapeutic effect of MePS2-1 siGRAMD1B in vitro and in vivo.
Having established the importance of targeting GRAMD1B in
OvCa treatment, we next examined if MePS2-1 modiﬁcation can
signiﬁcantly enhance the silencing efﬁciency of UM siGRAMD1B.
We found that MePS2-1 siGRAMD1B efﬁciently silenced
GRAMD1B both at the mRNA (70%, data not shown) and protein
(85%) level in HeyA8-MDR cell line in the presence of serum
(40 nM, Fig. 5a). This level of GRAMD1B knockdown was sig-
niﬁcantly better than that achieved by UM siGRAMD1B (85%
versus 50%). Consistent with our ﬁndings using siEphA2 and
siPTMS (Fig. 2d,e; Fig. 3b,c; Supplementary Fig. 5), MePS2-1
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viablity and (e) apoptosis in HeyA8-MDR cells. (f) Effect of knockdown of GRAMD1B on the sensitivity of HeyA8-MDR cells to paclitaxel or docetaxel
treatment. Cell viability is expressed as a percentage of that measured in siRNA monotherapy-treated wells. (g) Effect of GRAMD1B protein expression on
overall survival in OvCa patients (n¼ 156). Scale bar, 100 mm. (P-values obtained with (a–f) Student’s t-test or (g) log-rank test; (b) ***Po0.001 or
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modiﬁcation also signiﬁcantly enhances the serum and intracel-
lular stabilities of siGRAMD1B (Supplementary Fig. 14) and
increases its binding to Ago2 protein when compared with UM
siGRAMD1B (Fig. 5b). Let-7a was used as a normalizing control
for the Ago2 binding study as its expression is not altered by
GRAMD1B silencing (Supplementary Fig. 15).
Moving into an orthotopic mouse model, we injected HeyA8-
MDR cells into the peritoneal cavity and, after 1 week, mice were
divided into four treatment groups: (a) MePS2-1-siCon-DOPC,
(b) MePS2-1-siGRAMD1B-DOPC, (c) MePS2-1-siCon-DOPC
plus paclitaxel or (d) MePS2-1-siGRAMD1B-DOPC plus pacli-
taxel. Dosing was twice weekly for siRNA and weekly for
paclitaxel (at a sub-therapeutic 100 mg dose), followed by tumour
excision and quantiﬁcation after 5 weeks of treatment. No
signiﬁcant reduction in tumour burden was observed for sub-
therapeutic paclitaxel with MePS2-1-siCon-DOPC treatment
group, as expected (Fig. 5c). However, MePS2-1-siGRAMD1B-
DOPC alone resulted in 50% reduction in tumour burden,
consistent with our in vitro ﬁndings (Fig. 4d). Combining it with
paclitaxel induced a 55% further reduction in total tumour weight
compared with MePS2-1-siGRAMD1B-DOPC monotherapy,
indicating the potential for taxane sensitization after GRAMD1B
silencing. The reduction of GRAMD1B levels in tumours
by MePS2-1-siGRAMD1B-DOPC was signiﬁcant, with the
protein level being downregulated by 80% in tumours from mice
treated with MePS2-1-siGRAMD1B-DOPC (Fig. 5d). This
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downregulation of GRAMD1B in tumours was also signiﬁcantly
associated with the induction of cleaved caspase 3 (Fig. 5e). This
is consistent with the increased level of apoptotic cells observed
following GRAMD1B silencing in vitro (Fig. 4e). Replicating the
experiment with a different GRAMD1B-targeted siRNA sequence
in SKOV3-TR, another taxane-resistant OvCa model, produced a
similar therapeutic effect (Fig. 5f). In this model, mice treated
with both MePS2-1-siGRAMD1B-DOPC and paclitaxel had an
80% further decrease in tumour burden compared with mice
treated with MePS2-1-siGRAMD1B-DOPC alone, which again
indicated the role of GRAMD1B in taxane resistance. Impor-
tantly, in both of the models tested, there was no alteration in
mouse body weights in any of the treatment groups
(Supplementary Fig. 16).
Discussion
Recent advances in high-throughput genomic and computational
tools have facilitated the identiﬁcation of new targets with
translational potential34. Combining novel MePS2 siRNA
chemistry with a whole-genome lethality screen aimed at
identifying novel genes involved in taxane resistance, we
demonstrate, for the ﬁrst time, the feasibility of using highly
potent MePS2-modiﬁed siRNAs for effective therapeutic
targeting. We show that GRAMD1B, a gene identiﬁed through
our high-throughput screening and analyses, has both high
biological and clinical importance. Using it as a model system, we
demonstrate that robust gene silencing in tumours can be
achieved following systemic administration of MePS2-modiﬁed
siRNAs. This ultimately led to signiﬁcant re-sensitization of
chemoresistant ovarian tumours to taxane therapy.
Most of the chemical modiﬁcation strategies, to date, have
focused on improving siRNA stability in serum7. While this is
critical, improving siRNA potency at target sites following
systemic administration still remains the major obstacle to
clinical translation of siRNAs5,6. Through a systematic
approach, we have identiﬁed a unique combination of 20-OMe
and PS2 that signiﬁcantly improves stability and potency of
siRNAs simultaneously (Fig. 6). We ﬁrst conﬁrmed that the
increase in potency could not be explained by the design’s
enhanced stability, consistent with previous ﬁndings that this
mechanism has a limited role within rapidly dividing cells35, and
then investigated other potential causes.
We discovered that MePS2 modiﬁcation further enhances the
loading of siRNAs to RISC, compared with PS2 modiﬁcation,
resulting in enhanced silencing. While the addition of methyl
groups typically elevates Tm, we show here that the addition of
20-OMe to PS2-modiﬁed siRNAs does not increase the Tm of the
siRNA duplex, suggesting a unique property arising from this
combination. The computational modelling also indicates an
unusual favourable stereoelectronic effect on the siRNA backbone
following MePS2 modiﬁcation. These results indicate that MePS2
modiﬁcation can improve the interaction of siRNA with RISC via
several mechanisms, namely the thiol–protein interaction26,27,36,
modulation of Tm and altered stereoelectronics. This is in
contrast to currently existing modiﬁcations, where RISC loading
efﬁciency is dependent on alteration in Tm, thus leading to
variable silencing effects depending on the Tm of the sequences to
be modiﬁed20,37. Hence, MePS2 modiﬁcation has a unique
potential to provide more consistent, sequence-independent,
silencing effects compared with existing chemistries.
In summary, we show that 20-OMe and PS2 combination not
only signiﬁcantly increases the serum stability of siRNAs but also
triggers a more potent intrinsic RNAi response than the
individual modiﬁcations. In addition to its achiral nature that
favors clinical translation, we have demonstrated the ability of
MePS2 modiﬁcation to overcome major obstacles of bringing
siRNA therapeutics into the clinic. It is anticipated that further
understanding the unique and advantageous interaction between
20-OMe and PS2 moieties will facilitate the rational design of
highly potent and stable siRNAs in the near future.
Methods
Cell lines. The OvCa cell lines, SKOV3ip1 and HeyA8, were obtained from ATCC
and were maintained in RPMI 1,640 supplemented with 15% FBS and 0.1%
gentamicin sulphate (Gemini Bioproducts; Calabasas, CA)38. SKOV3-TR and
HeyA8-MDR were kind gifts from Dr Isaiah Fidler, Department of Cancer Biology,
University of Texas MD Anderson Cancer Centre and Dr Michael Seiden,
Department of Medicine, Massachusetts General Hospital, respectively.
SiRNA synthesis. SiRNAs were synthesized at AM Biotechnologies. All sequences
are listed in Supplementary Table 3. Modiﬁed and UM 21-nt RNAs (sense and
antisense strands) were synthesized on the 1 mmol scale on an Expedite 8909 DNA/
RNA Synthesizer using commercial available 50-DMT-20-O-TBDMS nucleoside
(ABz, CAc, GAc and U) phosphoramidite monomers and 50-DMT-20-OMe
nucleoside (ABz, CAc, GAc and U) phosphoramidite monomers as well as in house
produced 50-DMT-20-OMe nucleoside (ABz, CAc, GAc and U) thiophosphoramidite
monomers15,16,28. All oligonucleotides were synthesized in DMT-off mode. After
completion of the synthesis, the solid support was suspended in ammonium
hydroxide/methylamine (AMA) solution (prepared by mixing 1 volume of
ammonium hydroxide (28%) with 1 volume of 40% aqueous methylamine) and
heated at 65 C for 15min to release the product from the support and to complete
the removal of all protecting groups except the TBDMS group at the 20 position.
The solid support was ﬁltered, and the ﬁltrate was concentrated to dryness.
The obtained residue was resuspended in 115 ml of anhydrous DMF and then
heated for 5min at 65 C to dissolve the crude product. Triethyl amine (60ml)
was added to each solution, and the solutions were mixed gently. Triethyl
amine  3HF (75 ml) was added to each solution, and the tubes were then sealed
tightly and incubated at 65 C for 2.5 h. The reaction was quenched with 1.75ml
of DEPC-treated water. Puriﬁcation was performed on an Amersham Biosciences
P920 FPLC instrument ﬁtted with a Mono Q 10/100 GL column39. The
structures of the modiﬁed RNAs were conﬁrmed by ESI-MS and 31P-NMR.
The assembly of the resulting duplexes was conﬁrmed on a 4% agarose gel
electrophoresis. For in vivo experiments, ammonium counter cation was
replaced by sodium cation.
In vitro siRNA transfection and luciferase assays. Cells were transfected with
10–100 nmol l 1 of speciﬁed siRNAs using Lipofectamine 2000 or Lipofectamine
RNAiMax reagent (Invitrogen) at 3 ml reagent: 1 mg siRNA ratio21. Cells were
MePS2-1 siRNA UM siRNA
Enhanced serum
stability
Nuclease
degradation
Enhanced
RISC loading
RISC
mRNA cleavage
MePS2-1 siRNA Degraded siRNA
mRNA
siRNA (AS strand)
Delivery carrierUM siRNA
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siRNA activity
Figure 6 | A schematic representation of mechanisms by which MePS2
modiﬁcation enhances siRNA activity. MePS2-1 modiﬁcation enhances
serum stabilty of siRNAs and promotes the loading of the antisense strand
into RISC.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4459 ARTICLE
NATURE COMMUNICATIONS | 5:3459 | DOI: 10.1038/ncomms4459 |www.nature.com/naturecommunications 9
& 2014 Macmillan Publishers Limited. All rights reserved.
treated with siRNAs for 4 h in serum-free or 10% FBS-containing media before
incubation in fresh complete media for the speciﬁed timeframe.
GoClone pLightSwitch luciferase reporter constructs containing AS and S
siRNA target sequences were obtained from SwitchGear genomics (Menlo Park,
CA). AS construct contains the following sequence: 50-CAAAGGGTGGGACCTG
ATGCAGAACATCA TGAATGACATGCCGATCTACATGTACTCCGTGTGC
AACGTGATGTCTGGCGAC-30 . S construct contains the following sequence:
50-ACCTGATGCAGAACATCATGAACAT GTAGATCGGCATGTCATACTCC
GTGTGCAACGTGATGTCT-30 . SKOV3ip1 cells were transfected with FuGENE
HD reagent in a 96-well plate with speciﬁed siRNAs (100 nM) along with S or AS
reporter construct, and Cypridina TK control construct (pTK-Cluc)40. After 24 h of
transfection, luciferase activity was obtained using LightSwitch Dual Luciferase
assay kits. Luciferase activity was normalized with the Cypridina TK control
construct. All assays were performed in triplicate.
Quantitative reverse transcription PCR. RNA was isolated from cells, Ago2
pulldown products, blood samples and tissues using Trizol (Invitrogen) according
to the manufacturer’s protocol. Using 1 mg of RNA, cDNA was synthesized by
using a Verso cDNA kit (Thermo Scientiﬁc) as per the manufacturer’s instructions.
Analysis of mRNA levels was performed on a 7500 Fast Real-Time PCR System
(Applied Biosystems) with SYBR Green-based qRT–PCR. PCR was performed with
reverse-transcribed RNA and 100 ng ml 1 of forward and reverse primers in a total
volume of 20 ml (ref. 38). All primer sequences for mRNA detection are listed in
Supplementary Table 4. Each cycle consisted of 15 s of denaturation at 95 C and
1min of annealing and extension at 60 C (40 cycles). Stemloop PCRs for siRNA
detection were performed using TaqMan miRNA assays followed by SYBR Green-
based qRT–PCR41. Stemloop primers used to synthesize cDNA are listed in
Supplementary Table 5. Respective forward primers as well as a common reverse
primer used for qRT–PCR are listed in Supplementary Table 4. For miRNA
quantiﬁcation, total RNA was isolated using Trizol (Invitrogen) extraction.
TaqMan miRNA assays (Applied Biosystems) were used for reverse transcription
and qRT–PCR was performed according to the manufacturer’s instructions. For
microRNA detection, Ambion assay probe sets were used according to the
manufacturer’s protocol. The relative amount of mRNA/siRNA in each sample was
normalized to b-actin mRNA, RNU44, RNU6B or respective miRNAs.
Melting proﬁles of siRNAs. Complementary RNA strands were mixed in 10mM
Tris-HCl buffer (pH 7.4) with 100mM NaCl, and 0.1mM ethylenediaminete-
traacetic acid (EDTA) at a ﬁnal concentration of 2 mM. Annealing was performed
at a temperature gradient of 1.5 Cmin 1, from 85 to 15 C. Melting proﬁles were
measured using a temperature gradient of 1 Cmin 1, from 15 to 85 C, with the
detector set at 260 nm (n¼ 3–6).
CD measurements. CD spectra were recorded on a CD6 dichrograph
(Jabin-Yvon) using cells with 0.5 cm path length, 2 nm bandwidth and 1–2 s
integration time. Each spectrum was smoothed with a 25-point algorithm. The
spectra from 200–340 nm were recorded at 25 C in the same buffer as in the
melting experiments (n¼ 3). The concentration of the two complementary RNA
oligonucleotides was ca. 2 mM.
Western blot. Protein lysates were prepared from cultured cells or tumours using
modiﬁed RIPA buffer (50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% Triton, 0.5%
deoxycholate) plus 25 mgml 1 leupeptin, 10mgml 1 aprotinin, 2mM EDTA and
1mM sodium orthovanadate38. Membranes were probed with primary antibodies
against EphA2 (1:1,000, Millipore, 05-480), b-actin (1:5,000, Sigma, A5316),
vinculin (1:2,500, Sigma, V9131), GAPDH (1:5000, Sigma, G8795), Ago2 (1:100,
Wako Chemicals, 015-22031) and GRAMD1B (1:500, Sigma, HPA008557) in 5%
skim milk in TBS-T. Quantiﬁcation was performed using ImageJ. Full scans of
important western blots are provided in Supplementary Fig. 17.
Intracellular Ago2-binding study. Cells were lysed at 7 h post transfection using
ice-cold lysis buffer (50mM Tris-HCl at pH 7.5, 200mM NaCl, 0.5% Triton, 2mM
EDTA, 1mgml 1 heparin and protease inhibitor cocktail)42,43. Ago2 antibody
(Wako Chemicals, 015-22031, 20 ml) was absorbed onto magnetic protein G
Dynabeads (Invitrogen, 40 ml) by incubation at 4 C for 2 h on a rotator. The beads
were then washed twice with lysis buffer to remove unbound antibodies. Following
washing, beads were incubated with protein lysate (360 mg) overnight at 4 C on a
rotator. Following removal of unbound proteins, bound material was eluted from
beads using 50 ml of 0.1M glycine (pH 2.3) for 15min at RT. Eluted fractions were
neutralized immediately with an equal volume of 1M Tris-HCl (pH 8) and then
treated with 20 U of proteinase K for 10min at 65 C (ref. 44). The amount of
Ago2-bound siRNA was then quantiﬁed using stemloop PCR technique. For the
biotin-siRNA pulldown experiment, strepavidin beads were blocked and incubated
with cell lysates at 4 C for 2 h (ref. 42). The amount of siRNA-associated Ago2 was
quantiﬁed via western blotting.
Serum stability assay. SiRNAs (1.33mg) were incubated in 10ml of 10% FBS in
PBS at 37 C for up to 24 h. All samples were separated in 20% polyacrylamide gels.
The percentage of intact siRNA present was quantiﬁed using ImageJ.
Immunogenicity of siRNAs. Bone marrow progenitor cells were isolated from
C57BL/6 mice and were differentiated into dendritic cells in vitro for 7 days using
FLT3 ligand (100 ngml 1; PeproTech). Cells were treated with 75 nM of siRNAs
for 6 h in serum-free media using RNAiMax. A high interferon-inducing siRNA
sequence (BP1Mod2; Supplementary Table 3) and CpG2216 (1 mgml 1, Sigma)
were used as positive controls. The level of IFN-a and TNF-a in the culturing
media was assessed using murine IFN-a and TNF-a ELISA kits at 2, 6 and 24 h
following transfection (R&D Systems). For TLR7 experiments, peripheral blood
mononuclear cells were obtained from wild-type and TLR7-KO C57BL/6 mice and
were treated with 75 nM of siRNAs for 6 h. IFN-a and TNF-a levels in the cul-
turing media was measured 24 h post transfection. For in vivo studies, serum was
collected from mice at 2, 6 and 24 h post siRNA treatment and IFN-a and TNF-a
levels were measured as described above.
Liposomal nanoparticle preparation. SiRNAs for in vivo delivery were incor-
porated into DOPC liposomes21. DOPC and siRNA were mixed in the presence of
excess tertiary butanol at a ratio of 1:10 (w/w) siRNA/DOPC. Tween 20 was added
to the mixture in a ratio of 1:19 Tween 20:siRNA/DOPC. The mixture was
vortexed, frozen in an acetone/dry ice bath and lyophilized. Before in vivo
administration, this preparation was hydrated with PBS.
Orthotopic in vivo models of OvCa. Female athymic nude mice (8–12 weeks old)
were obtained from the National Cancer Institute, Frederick Cancer Research and
Development Center (Frederick, MD). All mouse studies were approved and
supervised by the MD Anderson Cancer Center Institutional Animal Care and Use
Committee. For therapeutic experiments, 10 mice were assigned per treatment
group. This sample size gave 80% power to detect a 50% reduction in tumour
weight with 95% conﬁdence. To establish intraperitoneal tumours, cells were
injected into the peritoneal cavity i.p. at a concentration of 5 106 cells per ml
(200 ml per injection). All mice were treated with siRNAs (2.5 or 5 mg for EphA2
and GRAMD1B experiments, respectively) twice weekly beginning at 1 week fol-
lowing tumour cell injection. Paclitaxel (100 mg) was injected i.p. once weekly. Mice
(n¼ 10 per group) were monitored for adverse effects and tumours were harvested
after 5 weeks of therapy or when any of the mice began to appear moribund.
Mouse weight, tumour weight and the number/location of tumour nodules were
recorded. Tumour tissues were ﬁxed in formalin for parafﬁn embedding or was
snap frozen for lysate preparation21. For gene silencing (1.25 and 2.5 mg), immune
toxicity (5 mg), pharmacokinetic (2.5 mg) and biodistribution studies (2.5 mg), single
dose of siRNA was administered i.p. once tumours became palpable. Blood and/or
tissues samples were collected at speciﬁed time points for RNA/protein extraction
or ELISA assay. For the ﬂuorescence-based biodistribution study, Cy5.5-labelled
siRNAs were administered i.p. and 48 h later, ﬂuorescence imaging of excised
tumour and organs was performed using the Xenogen IVIS 200 system40. Cy5.5
ﬂuorophore excitation (678 nm) and emission (703 nm) ﬁlters were used. Using
Living image 2.5 software, regions of interest were drawn for each organ and the
total radiant efﬁciency ps 1 mW 1 cm2 was measured.
Pharmacokinetic analysis. Blood concentrations of siRNA at the indicated times,
C(t), were expressed as pg siRNA per ml of blood. Pharmacokinetic parameters
were determined by ﬁtting the C(t) with a two-compartment model using the
MULTI programme45. The AUC of the blood concentration time was calculated by
integration of C(t) up to 72 h following administration. Volume of distribution was
calculated by dividing the injected dose by C(0). CLtotal was calculated by dividing
injected dose by AUC.
Microarray and pathway enrichment analysis. HeyA8-MDR cells were treated
with siGRAMD1B and total RNA was extracted 48 h following transfection using
mirVana RNA isolation labelling kit (Ambion). Five hundred nanograms of total
RNA were used for labelling and hybridization on a Human HT-12 v4 Beadchip
(Illumina) according to the manufacturer’s protocols46. After the bead chips were
scanned with an Illumina BeadArray Reader (Illumina), the microarray data were
normalized using the quantile normalization method in the Linear Models for
Microarray Data (LIMMA) package in the R language environment. The
expression level of each gene was transformed into a log2 base before further
analysis.
GEOID for the microarray data is GSE54459. The top 10 pathways perturbed by
siGRAMD1B treatment were identiﬁed using NetWalker software47. Each
interaction in the global network of biological relationships was scored based on
combined assessment of the network connectivity and the input data. Biological
pathways were ranked based on geometric P-values.
SiRNA lethality screen. SKOV3-TR cells used for the screen were maintained in
antibiotic-free RPMI1640 supplemented with 10% FBS48 and were authenticated
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prior to their utilization in the screen. For the screen, SKOV3-TR (2,000 cells per
well) were transfected using siRNAs in individual wells of black 384-well plates for
48 h. Transfection was performed using a pool of four individual siRNAs targeting
individual genes (siGenome Smart pool, G-004605, Dharmacon) using Dharmafect
1 (Dharmacon)49. SiTOX was used as a control for transfection efﬁciency. Non-
targeting siRNA number 4 (siOTP4, Dharmacon) was used as a transfection
control in all experiments. In summary, 0.2 ml of 20mM siRNA was mixed with
0.2 ml of Dharmafect 1 and 20 ml of Optimem medium (Invitrogen) for 20min in
a well of 384-well plate and overlaid with 80 ml of cell suspension (2,000 cells) in
antibiotic-free RPMI1640 supplemented with 10% FBS. This gave a ﬁnal siRNA
concentration of 40 nM per well. For each plate, four types of control were
included: siOTP4 as a negative control (16 wells), siTOX as a control for
transfection efﬁciency (8 wells), cells only (24 wells) and blank wells (16 wells).
Following siRNA treatment, cells were treated with paclitaxel (3.5 nM). All
experiments were performed at 37 C in the presence of 5% CO2. Finally,
cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte
trazolium bromide (MTT, USB Corporation) as per manufacturer’s instruction 3
days after treatment and signal was detected using a PHERAstar FS plate reader
(BMG Labtech). Following data collection, the values in each plate were centered
on 100 using median scaling49 and cell viabilities were expressed as percentages of
siOTP4-treated samples. Student’s t-test was used to examine chemosensitization
following conversion of raw values to log2 scale.
Immunohistochemistry analysis. Staining was performed in parafﬁn-embedded
tumour sections21. For patient samples, tissue microarray slides containing 156
OvCa samples were obtained from MD Anderson Cancer Center following
approval by the Institutional Review Board. Antigen retrieval was performed using
citrate buffer (pH 6) or Borg Decloaker solution (Biocare Medical, BD1000 S-250)
for GRAMD1B and cleaved caspase 3, respectively. Slides were incubated with
primary antibodies against GRAMD1B (1:100 dilution, Sigma, HPA008557) or
cleaved caspase 3 (1:200, BioCare Medical, CP229A) overnight, followed by
incubation with horseradish peroxidase-conjugated or biotinylated/streptavidin
anti-Rabbit secondary antibodies, respectively (Jackson Laboratory, 111-036-047
and BioCare Medical, GR602 H). The stained slides were scored by two
investigators blinded to the treatment groups or patient survival information. For
in vivo samples, 5–10 random ﬁelds at  200 magniﬁcation for each tumour were
examined. For patient samples, a scoring system, which considered both the
intensity of staining and the percentage of cells stained, was used46,50. H scores of
4100 and r100 were deﬁned as high and low expression, respectively.
Cell viability assays. HeyA8-MDR cells were transfected with siRNAs (100 nM)
on day 1 and 3 before paclitaxel or docetaxel treatment. Cell viability was assessed 3
days following taxane treatment using MTT assay as per manufacturer’s protocol.
Statistical analysis. Kaplan–Meier plots were constructed and a log-rank test was
used to determine differences among survival curves according to tumoral
GRAMD1B expression level46,50. Contingency tables and Fisher’s exact test or
w2 test were used to evaluate the relationship between death and categorical
variables. Multivariate analyses were performed with the use of a Cox proportional-
hazards model to examine the effects of tumoral GRAMD1B expression on death
from disease while adjusting for other covariates. w2 test was performed to assess
the effect of tumoral GRAMD1B expression on drug response. For siRNA lethality
screen, Student’s t-test was used to examine chemosensitization following
conversion of raw values to log2 scale. For other assays, Student’s t-test was
performed to examine the difference between control and treatment groups.
Apoptosis assay. Apoptosis was studied using the Annexin V apoptosis detection
kit (BD Biosciences) according to the manufacturer’s protocol38. Apoptotic cells
were analysed using a FACSCalibur ﬂow cytometer (BD Biosciences). CellQuest
Pro software (BD Biosciences) was used to determine the number of apoptotic cells.
Modelling of siRNA:PAZ domain interactions. Coordinates of the complex
between a 9 mer siRNA and the PAZ domain from human Argonaute eIF2c1 were
retrieved from the Protein Data Bank (http://www.rcsb.org; PDB ID code 1si2
(ref. 29)). The programme UCSF Chimera51 was used to convert the sequence of
the last four nucleotides in the siRNA from the 1si2 crystal structure to match the
sequence and chemistry of MePS2-1 (...ACUdCdU-30 andyAUMeS2GMeS2dTdT-
30 , respectively). Changes to reﬂect the chemistries of the Me-1 and PS2-1 siRNAs
were accomplished in a similar manner. Side chain torsion angles of C270 and
M273 were adapted in USCF Chimera, and the programme was used for measuring
distances and producing ﬁgures. The complex models generated were not subjected
to energy minimization with either molecular mechanics or dynamic approaches.
The important role of M273 in stabilizing the siRNA–PAZ interaction is reﬂected
by the change in Kd upon mutation of residue 273 from methionine to alanine29.
The side chain of M273 snakes along the terminal base pair of the siRNA duplex,
and the mutation to alanine abolishes this stacking interaction and doubles the Kd.
The effect of hydrophobic interactions between siRNAs and M273/C270 on Kd was
also examined.
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